New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for...

Summit, NJ, USA 07 Dec 2021 Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the relative...

Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published...

• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...

• Appoints Roberta Duncan as new program lead to drive technology advancement • Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza Summit, NJ, USA 19 Aug...

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Liverpool, UK 01 Jun 2021 Seqirus Liverpool is the...

This news release is intended for Health Professional media only. Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the...

Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention and influenza pandemic response, today presented new late-breaking data from a systematic review and meta-analysis at...